Email Updates

You are here

HVTN 112

Status
Ongoing
Phase
I
Principal Investigator(s)
Greg Wilson
Objective

The purpose of this study is to evaluate the safety and tolerability of an HIV-1 nef/tat/vif, env pDNA vaccine delivered with electroporation (EP), followed by a recombinant vesicular stomatitis virus (rVSV) HIV envC vaccine boost, in healthy, HIV-uninfected adults.

*Trial is in follow-up*

Prevention Option(s)
HIV Vaccine
Study Design
Double-blind
Arms and Assigned Interventions
Description
Participants will receive the HIV-1 nef/tat/vif, env pDNA vaccine at Day 0 and Months 1 and 3. They will receive the rVSV HIV envC vaccine boost at Months 6 and 9.
Mode of Delivery
Intramuscular
Products
rVSV
ARMs
Experimental
Description
Participants will receive placebo vaccine at Day 0 and Months 1, 3, 6, and 9.
Mode of Delivery
Intramuscular
ARMs
Placebo Comparator
Trial Sponsors
NIAID
March 2016
September 2019
Enrollment
15
18
Years
50
Years
Population
Women
Men
Sites

Case CRS

Cleveland, Ohio
United States of America

Penn Prevention CRS

Philadelphia, Pennsylvania
United States of America